Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2025.07.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal epinephrine: The need to have confidence in efficacy.
J Allergy Clin Immunol
August 2025
Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
Intranasal Epinephrine: Where Might It Fit in Guidelines for Managing Anaphylaxis.
J Allergy Clin Immunol Pract
August 2025
Division of Allergy and Immunology, Department of Pediatrics, the Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Recent Insights into the Epidemiology and Management of Anaphylaxis.
Balkan Med J
September 2025
Clinic of Allergy, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan
Anaphylaxis is a severe, rapidly developing systemic hypersensitivity reaction that can be life-threatening if not promptly identified and treated. Its global incidence is on the rise, especially among children, though fatal outcomes remain uncommon. This review summarizes the current understanding of anaphylaxis, covering its epidemiology, triggers, acute management, and strategies for long-term prevention, with emphasis on cases caused by food, medications, and insect stings.
View Article and Find Full Text PDFAdvances in the treatment of anaphylaxis: intranasal and sublingual versus intramuscular epinephrine.
Curr Opin Allergy Clin Immunol
October 2025
Department of Pediatrics, Children's Hospital Colorado, School of Medicine, Section of Allergy and Immunology, University of Colorado, Aurora, Colorado, USA.
Purpose Of Review: Epinephrine is universally considered the standard of care for the treatment of severe allergic reactions, including anaphylaxis, and, until recently, was preferentially recommended to be given intramuscularly in the thigh. However, newer routes of administration have been studied, with the intranasal route recently approved by regulatory agencies.
Recent Findings: Pharmacokinetic and pharmacodynamic studies suggest that noninjectable epinephrine routes (e.
Epinephrine Nasal Spray Improves Allergic Symptoms in Patients Undergoing Oral Food Challenge, Phase 3 Trial.
J Allergy Clin Immunol Pract
July 2025
ARS Pharmaceuticals Operations Inc, San Diego, Calif. Electronic address:
Background: Rapid administration of epinephrine is the only approved first-line treatment for severe allergic reactions or anaphylaxis. Despite its well-established history of safety and efficacy, patients and caregivers have reported significant reluctance to administer epinephrine, largely owing to concerns about the injection. An epinephrine nasal spray (neffy) was recently approved as the first needle-free epinephrine option for the treatment of severe allergic reactions.
View Article and Find Full Text PDF